3,148
Participants
Start Date
June 30, 2006
Primary Completion Date
January 31, 2007
Study Completion Date
January 31, 2008
Rivaroxaban (Xarelto, BAY59-7939)
Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
Enoxaparin
Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
Placebo: tablet of Rivaroxaban
Placebo tablet of rivaroxaban administered once daily in the evening.
Placebo: syringes of Enoxaparin
Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
Baerum Postterminal
Sofia
Kongsvinger
Lillehammer
Hvidovre
Herlev
Gjøvik
Hørsholm
Plovdiv
Pleven
Silkeborg
Viborg
Johnstown
State College
Towson
Greensboro
Charleston
Decatur
Jacksonville
Pensacola
DeLand
Hollywood
Clearwater
Pinellas Park
Panevezys
Birmingham
Tuscaloosa
Guadalajara
Kfar Saba
Kaunas
Guadalajara
Zapopan
Cincinnati
Petah Tikva
Edo. de Mexico
Holon
Missoula
Monterrey
Tel Aviv
Monterrey
Ẕerifin
Little Rock
Oklahoma City
Karachi
Plano
Dallas
Grapevine
Houston
San Antonio
San Antonio
Lubbock
Englewood
Centennial
Denver
Meridian
Boise
Phoenix
Beersheba
Encinitas
La Jolla
Klaipėda
Fountain Valley
Bakersfield
Yuba City
Mérida
Spokane
New Delhi
Ludhiana
Ahmedabad
Ahmedabad
Baroda
Pune
Pune
Secundrabad
Hyderabad
Bangalore
Bangalore
Torrance
Boynton Beach
Teaneck
Red Deer
Kelowna
Penticton
Fredericton
Ajax
Brantford
Greater Sudbury
Oakville
Oshawa
Ottawa
Peterborough
Scarborough Village
Scarborough Village
Thunder Bay
Woodstock
Charlottetown
Montreal
Montreal
Hellerup
Secunderabad
Chennai
Hyderabad
Karachi
Kielce
Colombo-80
Ragama
Sri Jayewardenepura Kotte
Kaunas
Vilnius
Bydgoszcz
Elblag
Gdansk
Gmina Końskie
Krakow
Lublin
Sosnowiec
Warsaw
Warsaw
Gothenburg
Hässleholm
Örebro
Stockholm
Vaxjo
Västervik
Lead Sponsor
Bayer
INDUSTRY